SciBase

13/11/2024

Exciting news from SciBase! A recent study published by researchers at Koç University in Istanbul has shown promising results using EIS to monitor treatment outcomes in a young patient with severe atopic dermatitis. The study highlights the potential of Nevisense in evaluating treatment efficacy and improving patient outcomes in dermatology. We are proud to be at the forefront of innovation in healthcare and look forward to the potential impact our platform can have in improving patients' lives.
The full article can be found here: https://doi.org/10.24953/turkjpediatr.2024.4902

12/11/2024

In collaboration with the SKIN Research Group, this new study aims to deepen the investigation of Electrical Impedance Spectroscopy (EIS) as an innovative tool for the early identification of infants at risk of developing atopic conditions, including atopic dermatitis, asthma, and hay fever.
Read the PM in full: https://investors.scibase.se/en/press/scibase-announces-collaboration-prediction-atopic-dermatitis-infants-2279519

18/10/2024

Shaping the Future of Skin Barrier and Melanoma Management! For two full days, our Swedish ELT and U.S. teams united to set the strategy for advancing skin barrier health and melanoma management. Together, we’re driving progress, setting new standards, and leading the way to a brighter, healthier future for patients worldwide.
​
hashtag hashtag hashtag hashtag hashtag

27/09/2024

SciBase announces sale of Nevisense to National Institutes of Health in US! This represents a major milestone for SciBase and demonstrates the high quality and innovative nature of Nevisense for research.
Read the release in full:
https://investors.scibase.se/en/press/scibase-announces-sale-nevisense-nih-us-2267312

27/09/2024

Fighting cancer with high-tech! Dr. Jürgen Ellwanger is a passionate dermatologist who often faces the negative consequences of sun exposure in his practice. When examining suspicious skin changes or moles, Dr. Ellwanger uses, among other things, the advanced non-invasive system for precise diagnostics.
Read the article here:

Dr. Jürgen Ellwanger ist Dermatologe aus Leidenschaft und behandelt in seiner Praxis häufig die negativen Folgen von Sonneneinstrahlung.

26/09/2024

SciBase announces today a partnership with Seraly Dermatology in Pittsburgh, Pennsylvania. The strategic collaboration will allow SciBase to continue to broaden access to the Nevisense test to patients across the US, and further their commitment to the early detection of melanoma, when the disease is almost 100% curable. Seraly Dermatology will integrate several Nevisense systems into their skin cancer detection workflow.
https://investors.scibase.se/en/press/scibase-expands-new-market-pennsylvania-and-receives-first-order-large-dermatology-practice

20/09/2024

From productive discussions at our US team meeting to valuable insights during client visits – it’s all about collaboration and growth! Excited to see how these moments pave the way for further expansion in the US, ultimately driving our mission to save patients' lives!
hashtag hashtag hashtag hashtag hashtag

11/09/2024

With our amazing DACH team setting the strategy for even further success!

04/09/2024

https://www.medicaldevice-network.com/news/new-report-backs-scibases-melanoma-detection-ai-device/?cf-view

The consensus report found that the melanoma detection device can improve clinician decision making and in the early detection of skin cancer.

02/09/2024

New US Consensus Report supports for its ability to significantly enhance the diagnostic assessment and clinical decision-making for early melanoma at point of care. The report, authored by leading U.S. clinicians and scientists, evaluated multiple diagnostic tools and was published in the renowed Journal of Drugs in Dermatology.

Read the report here : https://jddonline.com/articles/advances-in-technology-melanoma-diagnosis-prognosis-an-expert-consensus-panel-S1545961624P8365X/

23/08/2024

SciBase CEO Pia Renaudin proudly shares the highlights from our newly released Q2 report, showcasing an impressive 31% sales growth and a strong gross margin of 69%. Read more on Pia's insights here:
https://scibase.com/uk/we-continue-our-momentum-across-all-markets/

15/08/2024

Let us introduce Leda Beaty as our new Head of Commercial Operations in the US! With over 20 years of experience in the pharmaceutical and medtech industries, particularly in dermatology, Leda brings a wealth of knowledge and expertise to our team. Her impressive background includes key leadership roles at renowned companies such as Aventis, Amgen, Arthrex, and DermTech.

Leda's deep industry insights and extensive network will be instrumental in driving the successful launch of Nevisense. She will lead efforts to build high-performing teams, establish markets, and accelerate sales growth.
We are excited to see the positive impact Leda will have as she helps us drive innovation and growth across the US. Welcome aboard, Leda!